{"result": "(\"entity\"<|>IPILIMUMAB<|>ORGANIZATION<|>Ipilimumab is a drug used in immunotherapy for treating different tumors, including melanoma, and is known to cause hypophysitis as a common adverse effect.)\n##\n(\"entity\"<|>HYPERPROLACTINEMIA<|>EVENT<|>Hyperprolactinemia is a condition characterized by elevated levels of prolactin in the blood, which can lead to various symptoms including menstrual irregularities and infertility.)\n##\n(\"entity\"<|>PROLACTIN<|>ORGANIZATION<|>Prolactin is a hormone whose levels are monitored in patients, especially those undergoing treatment with certain medications like risperidone.)\n##\n(\"entity\"<|>RISPREDONE<|>ORGANIZATION<|>Risperidone is a medication that can elevate prolactin levels and is associated with hyperprolactinemia.)\n##\n(\"entity\"<|>ALBAREL F<|>PERSON<|>Albarel F is one of the authors referenced in the study on ipilimumab-induced hypophysitis.)\n##\n(\"entity\"<|>GAUDY C<|>PERSON<|>Gaudy C is one of the authors referenced in the study on ipilimumab-induced hypophysitis.)\n##\n(\"entity\"<|>CASTINETTI F<|>PERSON<|>Castinetti F is one of the authors referenced in the study on ipilimumab-induced hypophysitis.)\n##\n(\"entity\"<|>CARRÉ T<|>PERSON<|>Carré T is one of the authors referenced in the study on ipilimumab-induced hypophysitis.)\n##\n(\"entity\"<|>MORANGE I<|>PERSON<|>Morange I is one of the authors referenced in the study on ipilimumab-induced hypophysitis.)\n##\n(\"entity\"<|>CONTE-DEVOLX B<|>PERSON<|>Conte-Devolx B is one of the authors referenced in the study on ipilimumab-induced hypophysitis.)\n##\n(\"entity\"<|>SNYDER PJ<|>PERSON<|>Snyder PJ is one of the authors referenced in the studies on hyperprolactinemia.)\n##\n(\"entity\"<|>VILLAR-TAIBO R<|>PERSON<|>Villar-Taibo R is one of the authors referenced in the studies on prolactin disorders.)\n##\n(\"relationship\"<|>IPILIMUMAB<|>HYPERPROLACTINEMIA<|>Ipilimumab is known to cause hypophysitis, which can lead to hyperprolactinemia as a side effect<|>7)\n##\n(\"relationship\"<|>RISPREDONE<|>HYPERPROLACTINEMIA<|>Risperidone can elevate prolactin levels, contributing to the condition of hyperprolactinemia<|>8)\n##\n(\"relationship\"<|>ALBAREL F<|>IPILIMUMAB<|>Albarel F is an author of a study discussing the effects of ipilimumab, including its association with hypophysitis<|>5)\n##\n(\"relationship\"<|>GAUDY C<|>IPILIMUMAB<|>Gaudy C is an author of a study discussing the effects of ipilimumab, including its association with hypophysitis<|>5)\n##\n(\"relationship\"<|>CASTINETTI F<|>IPILIMUMAB<|>Castinetti F is an author of a study discussing the effects of ipilimumab, including its association with hypophysitis<|>5)\n##\n(\"relationship\"<|>CARRÉ T<|>IPILIMUMAB<|>Carré T is an author of a study discussing the effects of ipilimumab, including its association with hypophysitis<|>5)\n##\n(\"relationship\"<|>MORANGE I<|>IPILIMUMAB<|>Morange I is an author of a study discussing the effects of ipilimumab, including its association with hypophysitis<|>5)\n##\n(\"relationship\"<|>CONTE-DEVOLX B<|>IPILIMUMAB<|>Conte-Devolx B is an author of a study discussing the effects of ipilimumab, including its association with hypophysitis<|>5)\n##\n(\"relationship\"<|>SNYDER PJ<|>HYPERPROLACTINEMIA<|>Snyder PJ is an author of studies that discuss the causes and clinical manifestations of hyperprolactinemia<|>5)\n##\n(\"relationship\"<|>VILLAR-TAIBO R<|>HYPERPROLACTINEMIA<|>Villar-Taibo R is an author of studies that discuss prolactin disorders, including hyperprolactinemia<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: pofisarias (incluida la PRL), por hipofisitis (opción A falsa: respuesta correcta). Este fármaco                                                              farmacológica, en la mayoría de los casos no va a superar los 100 ng/ml, salvo la risperidona,\n        forma parte de la inmunoterapia empleada en diferentes tumores, como el melanoma, y la                                                                        que puede producir aumentos de hasta 300-400 ng/ml. Por tanto, se recomienda realizar una\n        hipofisitis       es uno de sus efectos adversos más comunes. En la mayoría de los casos, el diag-                                                            RMN hipofisaria para descartar prolactinoma en pacientes que toman un                                                           fármaco que eleva\n        nóstico se realiza por la presencia de cefalea, con aumento hipofisario en la RMN y desarrollo                                                                PRL a valores superiores a100 ng/ml, excepto en el caso de la risperidona, en el que se solici-\n        de déficits hormonales que pueden persistir a largo plazo (sobre todo el corticotropo). Es im-                                                                tará la RMN solo si los niveles superan los 300 ng/ml (respuesta C).\n        portante        monitorizar las hormonas adenohipofisarias en estos pacientes, sobre todo a partir\n        del tercer ciclo del fármaco,                    que es cuando se suelen producir las hipofisitis por ipilimumab.                                                                                                                    PRL (ng/ml)\n        Referencias:\n        •  Albarel F, Gaudy C, Castinetti F, Carré T, Morange I, Conte-Devolx B, et al. Long-term follow-up of ipilimumab-induced hypophysitis, a                                          20                    40                   100                    200                   500                  1000\n           common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172(2):195-204.\n\n\n\n                                                                                                                                                                                   Límite superior de la                       Compresión del tallo                         Macroprolactinoma\n    33  Respecto a la hiperprolactinemia, señale la afirmación incorrecta:                                                                                                        normalidad del rangode PRL              hipofisiario por masas selares\n        A. La hiperprolactinemia leve (inferior a 50 ng/ml) puede producir una fase luteal corta\n             e infertilidad                                                                                                                                                                 Estrés de la venopunción, pulsatividad de la PLR     Prolactinoma (micro/macro),                      Prolactinoma gigante\n                                                                                                                                                                                            Macroprolactinemia, fármacos, hipotiroidismo,         fármacos (risperidona hasta\n                                                                                                                                                                                             enfermedad renal crónica (en fase terminal y         300-400 ng/ml, fenotiazidas,\n        B. La hiperprolactinemia en el varón produce hipogonadismo con aumento de la secreción                                                                                              diálisis puede aumentar x10 el límite superior)        sulpirida, metoclopramida)\n             de LH.\n        C. En todos los pacientes en tratamiento con risperidona y con hiperprolactinemia\n             superior a 300 ng/ml debe realizarse                              una RMN hipofisaria.                                                                   Figura 2. Relación entre la etiología de la hiperprolactinemia y los niveles de PRL.\n        D.   La hiperprolactinemia familiar es debida a una mutación que provoca pérdida                                                                              Existen casos de hiperprolactinemia familiar asociados a mutaciones germinales de pérdi-\n             de función del gen que codifica el receptor de prolactina                                                                                                da de función del gen del receptor de la PRL (respuesta D).\n                                                                                                                                                                      Referencias:\n        COMENTARIO                                                                                                                                                    •  Snyder PJ. Causes of hyperprolactinemia. En: Cooper DS, Martin KA, eds. UpToDate. Waltham, MA: UpToDate Inc.\n                                                                                                                                                                         https://www.uptodate.com (acceso 29 de abril de 2019).\n        Correlación entre clínica y niveles de PRL. La hiperprolactinemia causa típicamente sinto-                                                                    •  Snyder PJ. Clinical manifestations and evaluation of hyperprolactinemia. En: Cooper DS, Martin KA, eds. UpToDate.\n        matología en mujeres premenopáusicas y varones, pero no en mujeres posmenopáusicas.                                                                              Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso el 29 de abril de 2019).\n                                                                                                                                                                      •  Villar-Taibo R, Sifontes-Dubon M, Bernabeu-Moron I, Casanueva FF. Prolactin excess and deficiency: Epidemiology, causes\n        La clínica más habitual en la mujer es la alteración menstrual relacionada con el hipogona-                                                                      (excluding prolactin-secreting pituitary tumors). En: Tritos NA, Klibansky A. Prolactin disorders. From basic science to clinical\n                                                                                                                                                                         management. 1.ª ed. Springer Nature Switzerland AG: Humana press; 2019.\n        dismo secundario a la hiperprolactinemia. Los síntomas tienen una correlación\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}